Pacific Biosciences Of California (PACB) Gross Profit (2010 - 2026)

Pacific Biosciences Of California has reported Gross Profit for 17 years, with the latest figure at $12.6 million in Q2 2026.

• On a quarterly basis, Gross Profit fell 13.93% year-over-year to $12.6 million in Q2 2026; TTM through Jun 2026 was $57.9 million, a 73.62% increase from a year earlier, with the FY2025 full-year figure at $45.8 million, up 22.79% from the prior year.
• Gross Profit was $12.6 million for Q2 2026 at Pacific Biosciences Of California, down from $12.8 million in the prior quarter.
• The five-year high for Gross Profit was $17.9 million in Q3 2023, with the low at -$1.4 million in Q1 2025.
• Average Gross Profit over 5 years is $11.7 million, with a median of $12.7 million recorded in 2026.
• The sharpest annual moves came in 2025 and 2026: Gross Profit plunged 112.15% in 2025, then soared 1036.62% in 2026.
• Over 5 years, Gross Profit stood at $5.1 million in 2022, then surged by 86.21% to $9.6 million in 2023, then increased by 5.09% to $10.1 million in 2024, then soared by 64.7% to $16.6 million in 2025, then dropped by 23.71% to $12.6 million in 2026.
• The last three Gross Profit figures came in at $12.6 million (Q2 2026), $12.8 million (Q1 2026), and $16.6 million (Q4 2025), per Business Quant data.